Abbott recently launched a smartphone app that works with both its FreeStyle Libre 2 and FreeStyle Libre 3 CGM systems.

Medtronic (NYSE:MDT) announced today that it submitted 510(k) applications to the FDA seeking clearance for an interoperable ...

In a head-to-head study, three continuous glucose monitoring systems showed different measurements in the same person, which ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Medtronic has secured a green light from the FDA to connect its latest automated insulin pump with its newest continuous ...

Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day period.

it is facing stiff competition from Abbott’s ABT FreeStyle Libre CGM device. The ABT’s FreeStyle Libre 3 offers automatic glucose readings every minute, improved accuracy and a reduced size ...

Medtronic's 780G insulin pump automates much of the insulin delivery and can be integrated its own CGM or Libre. Though these competitive features could have peeled some Dexcom users away on the ...

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

A new randomised clinical trial – carried out by researchers at the University of Bath in the UK – found that a CGM sold by Abbott (the Freestyle Libre 2) "systemically overestimated" glucose ...

Within Diabetes Care, ABT is driving robust growth through its flagship, sensor-based CGM system — FreeStyle Libre. However, currency fluctuations may restrict Abbott’s growth potential.